Welcome to our dedicated page for NetraMark Holdings news (Ticker: AINMF), a resource for investors and traders seeking the latest updates and insights on NetraMark Holdings stock.
NetraMark Holdings Inc. reports developments tied to artificial intelligence for clinical trial optimization and precision medicine in the pharmaceutical industry. Its recurring updates center on the NetraAI platform, which is designed to analyze complex clinical datasets, identify model-derived patient subgroups, and support patient stratification, enrichment strategies, and trial-design decisions.
Company news commonly covers pharmaceutical and research collaborations, contracts to analyze clinical trial data, peer-reviewed work, conference presentations, and clinical leadership additions. Reported therapeutic areas include central nervous system disorders, depression, Alzheimer’s disease, oncology, and regulated botanical wellness, with emphasis on explainable analytics, biomarker-guided insights, and responder or placebo-sensitive patient populations.
NetraMark (OTCQB: AINMF) announced a peer-reviewed article published April 9, 2026, in Frontiers in Pharmacology proposing a testable hypothesis linking psychedelics, calcium/phosphate biology, and possible spin-dependent processes.
The paper, led by NetraMark founders, frames inter-individual treatment variability as structured biological heterogeneity and outlines a translational pathway to biomarker-guided, explainable-AI trial design aligned with NetraAI platform capabilities.
NetraMark (OTCQB: AINMF) announced a strategic research collaboration with Fondazione per la Medicina Personalizzata to analyze the ROME Phase II oncology trial dataset (NCT04591431) using NetraMark's NetraAI platform. The ROME trial randomized 400 patients and reported improved overall response rate and progression-free survival for tailored treatment versus standard of care.
The collaboration will seek Model-Derived Subgroups and evaluate endpoints including PFS, ORR, OS, time to treatment failure, and safety, subject to data availability and joint governance.
NetraMark (OTCQB: AINMF) presented a poster at the AD/PD 2026 conference (March 17-21) showing that its explainable AI, NetraAI, identified two treatment-responsive subgroups in the Phase 3 A4 solanezumab dataset.
Findings include biologically interpretable subgroups with preserved limbic/temporal network integrity and effect sizes up to Cohen’s d 1.52, suggesting AI-enabled precision enrichment may reveal masked therapeutic signals.
NetraMark (OTCQB: AINMF) signed a contract with a leading global biopharmaceutical company to analyze data from a Phase 2 depression clinical trial using its NetraAI platform. The engagement aims to identify patient subpopulations, evaluate treatment response patterns, and inform future study design with AI-driven precision insights.
NetraAI applies a dynamical systems framework to multi-dimensional, small clinical datasets to stratify high-effect-size cohorts and translate findings into clinically meaningful trial enrichment criteria.
NetraMark (OTCQB: AINMF) closed the second and final tranche of a non-brokered private placement on Feb 18, 2026, issuing 390,000 Units at $1.00 each for $390,000. The Offering raised aggregate gross proceeds of $3.5 million via 3,500,000 Units.
Each Unit includes one common share and one-half warrant; each whole warrant is exercisable at $1.35 for two years. Post-closing, there are 92,223,699 common shares outstanding. Securities are subject to a four-month-and-one-day hold ending June 19, 2026, and are not registered in the United States.
NetraMark (AIAI / OTCQB: AINMF) announced it will uplist to the Toronto Stock Exchange. The Company will voluntarily delist from the Canadian Securities Exchange effective close of market Feb 17, 2026 and commence TSX trading at market open Feb 18, 2026 under symbol AIAI.
The Common Shares will remain listed on the OTCQB as AINMF and on the Frankfurt exchange as PF0. Shareholders are not required to take any action. Management said the TSX listing should enhance access to institutional investors and support commercial adoption of NetraAI.
NetraMark Holdings (OTCQB: AINMF; CSE: AIAI; Frankfurt: PF0) named Lawrence Guy to its Board of Directors on January 29, 2026.
Mr. Guy brings capital-markets and investment-management experience, a CFA designation, prior CFO and portfolio-management roles, and current directorships at multiple TSX-V issuers to support NetraMark’s growth and governance.
NetraMark (OTCQB: AINMF) closed the first tranche of a non-brokered private placement for $3,110,000 by issuing 3,110,000 Units at $1.00 each. Each Unit includes one common share and one-half warrant exercisable at $1.35 for two years. There are now 91,778,520 common shares outstanding. Insiders purchased 2,060,000 Units; the securities are subject to a 4-month-and-a-day hold expiring May 28, 2026. The company received commitments for a second tranche of $390,000 expected to close in the near term, and intends to use proceeds for working capital and general corporate purposes.
NetraMark (OTCQB: AINMF) retained LodeRock Advisors for strategic investor relations and capital markets communications services, effective January 22, 2026. The engagement includes a 12-month IR strategy, marketing schedule, investor targeting, outreach, non-deal roadshows coordination with investment dealers, and ongoing capital markets counsel.
Under the agreement NetraMark will pay LodeRock a monthly fee of CAD $11,000. Services continue until terminated by either party with 60 days’ written notice. No securities or ownership interest will be issued to LodeRock or its executives; the relationship is arm’s length.
NetraMark (OTCQB: AINMF) announced a non-brokered private placement of up to 3,500,000 units at $1.00 CDN per unit to raise up to $3.5M CDN. Each unit consists of one common share and one-half warrant; each whole warrant allows purchase of one share at $1.35 for two years from closing. Securities will be subject to a statutory 4-month plus 1 day hold under Canadian law and will not be registered in the United States. Net proceeds are intended for general working capital and advancement/commercialization of the NetraAI platform and support of biopharmaceutical engagements.